Positive aspects, negative aspects and limitations of plasma therapy with special reference to COVID-19

Nagoba, Basavraj; Gavkare, Ajay; Jamadar, Nawab; Mumbre, Sachin; Selkar, Sohan P

doi:10.1016/j.jiph.2020.08.011

Cited by 35 publications

(40 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The plasma therapy has been in use in several countries. In this regard, it should also be mentioned that monoclonal antibodies have also been approved for use in humans with COVID-19 disease ( Focosi and Farrugia, 2020 ; Nagoba et al, 2020 ). Further, results of the seroprevalence studies using IgG and IgM antibody tests can be used as evidence of past exposure to the virus at the population level.…”

Section: Discussionmentioning

confidence: 99%

Landscape of humoral immune responses against SARS-CoV-2 in patients with COVID-19 disease and the value of antibody testing

Mahalingam

Peter

et al. 2021

Heliyon

View full text Add to dashboard Cite

A new pandemic is ongoing in several parts of the world. The agent responsible is the newly emerged severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). The symptoms associated with this virus are known as the coronavirus disease-2019 (COVID-19). In this review, we summarize the published data on virus specific antibodies in hospitalized patients with COVID-19 disease, patients recovered from the disease and the individuals who are asymptomatic with SARS-CoV-2 infections. The review highlights the following: i) an adjunct role of antibody tests in the diagnosis of COVID-19 in combination with RT-PCR; ii) status of antibodies from COVID-19 convalescent patients to select donors for plasma therapy; iii) highlights the potential confounding effects of other coronaviruses, measles, mumps and rubella in antibody testing due to homology of certain viral genes; and iv) elaborates the role of antibody testing for conducting surveillance in populations, incidence estimation, contact tracing and epidemiologic studies.

show abstract

Section: Discussionmentioning

confidence: 99%

Landscape of humoral immune responses against SARS-CoV-2 in patients with COVID-19 disease and the value of antibody testing

Mahalingam

Peter

et al. 2021

Heliyon

View full text Add to dashboard Cite

show abstract

“…There is growing evidence that early infusion is effective in preventing disease worsening but its success relies on the use of plasma units with high titers of SARS-CoV-2-specific antibodies and early administration [13, 41-44]. Limitations for this treatment include donor eligibility (exclusion criteria apply), willingness of recovered persons to donate (probably more than one time), early administration, logistic issues, among others [45, 46]. Other antibody-based therapies have been developed to replace the use of convalescent plasma, such as monoclonal antibodies and hyperimmune equine serum, but at higher costs.…”

Section: Discussionmentioning

confidence: 99%

Dynamics of SARS-CoV-2-specific antibodies during and after COVID19: Lessons from a biobank in Argentina

Longueira

Polo

Turk

et al. 2021

Preprint

View full text Add to dashboard Cite

BackgroundBiobanks are instrumental for accelerating research. Early in SARS-CoV-2 pandemic, the Argentinean Biobank of Infectious Diseases (BBEI) initiated the COVID19 collection and started its characterization.MethodsBlood samples from subjects with confirmed SARS-CoV-2 infection either admitted to health institutions or outpatients, were enrolled. Highly exposed seronegative individuals, were also enrolled. Longitudinal samples were obtained in a subset of donors, including persons who donated plasma for therapeutic purposes (plasma donors). SARS-CoV-2-specific IgM and IgG levels, IgG titers and IgG viral neutralization capacity were determined.FindingsOut of 825 donors, 57.1% were females and median age was 41 years (IQR 32-53 years). Donors were segregated as acute or convalescent donors, and mild versus moderate/severe disease donors. Seventy-eight percent showed seroconversion to SARS-CoV-2 specific antibodies. Specific IgM and IgG showed comparable positivity rates in acute donors. IgM detectability rate declined in convalescent donors while IgG detectability remained elevated in early (74,8%) and late (83%) convalescent donors. Among donors with follow-up samples, IgG levels seemed to decline more rapidly in plasma donors. IgG levels were higher with age, disease severity, number of symptoms, and was more durable in moderate/severe disease donors. Levels and titers of anti-spike/RBD IgG strongly correlated with neutralization activity against WT virus.InterpretationThe BBEI-COVID19 collection served a dual role in this SARS-CoV-2 global crisis. First, it feed researchers and developers transferring samples and data to fuel research projects. Second, it generated highly needed local data to understand and frame the regional dynamics of the infection.FundingThis work was supported by a grant from the Agencia Nacional de Promoción de la Investigación, el Desarrollo Tecnológico y la Innovación (Agencia I+D+i) from Argentina through an extraordinary funding opportunity to improve the national response to COVID19 (Proyecto COVID N° 11, IP 285).

show abstract

“…Donor eligibility requires donors consenting to donate plasma should meet the eligibility criteria for standard blood donation; e.g., for CPT, the donor must be negative for the SARS-CoV-2 test, free from COVID-19 symptoms, etc. [ 16 , 96 , 97 ]. A lack of neutralizing antibodies in the donor (recently recovered patient) plasma can hinder the preparation of CP for treating cases, and these antibodies last for only a few weeks to months.…”

Section: Convalescent Plasma Therapy (Cpt)mentioning

confidence: 99%

The Rise of SARS-CoV-2 Variants and the Role of Convalescent Plasma Therapy for Management of Infections

Moubarak

Kasozi

Hetta

et al. 2021

Life

View full text Add to dashboard Cite

Novel therapies for the treatment of COVID-19 are continuing to emerge as the SARS-Cov-2 pandemic progresses. PCR remains the standard benchmark for initial diagnosis of COVID-19 infection, while advances in immunological profiling are guiding clinical treatment. The SARS-Cov-2 virus has undergone multiple mutations since its emergence in 2019, resulting in changes in virulence that have impacted on disease severity globally. The emergence of more virulent variants of SARS-Cov-2 remains challenging for effective disease control during this pandemic. Major variants identified to date include B.1.1.7, B.1.351; P.1; B.1.617.2; B.1.427; P.2; P.3; B.1.525; and C.37. Globally, large unvaccinated populations increase the risk of more and more variants arising. With successive waves of COVID-19 emerging, strategies that mitigate against community transmission need to be implemented, including increased vaccination coverage. For treatment, convalescent plasma therapy, successfully deployed during recent Ebola outbreaks and for H1N1 influenza, can increase survival rates and improve host responses to viral challenge. Convalescent plasma is rich with cytokines (IL-1β, IL-2, IL-6, IL-17, and IL-8), CCL2, and TNFα, neutralizing antibodies, and clotting factors essential for the management of SARS-CoV-2 infection. Clinical trials can inform and guide treatment policy, leading to mainstream adoption of convalescent therapy. This review examines the limited number of clinical trials published, to date that have deployed this therapy and explores clinical trials in progress for the treatment of COVID-19.

show abstract

Positive aspects, negative aspects and limitations of plasma therapy with special reference to COVID-19

Cited by 35 publications

References 28 publications

Landscape of humoral immune responses against SARS-CoV-2 in patients with COVID-19 disease and the value of antibody testing

Landscape of humoral immune responses against SARS-CoV-2 in patients with COVID-19 disease and the value of antibody testing

Dynamics of SARS-CoV-2-specific antibodies during and after COVID19: Lessons from a biobank in Argentina

The Rise of SARS-CoV-2 Variants and the Role of Convalescent Plasma Therapy for Management of Infections

Contact Info

Product

Resources

About